Exagen (NASDAQ:XGN) Announces Earnings Results, Beats Expectations By $0.07 EPS

Exagen (NASDAQ:XGN) released its quarterly earnings results on Tuesday. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.07, Zacks reports. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. Exagen updated its Q1 2025 guidance to EPS.

Exagen Price Performance

XGN traded up $0.27 on Tuesday, hitting $3.12. 19,676 shares of the company were exchanged, compared to its average volume of 159,301. The business’s fifty day moving average is $3.80 and its 200 day moving average is $3.57. Exagen has a fifty-two week low of $1.30 and a fifty-two week high of $6.22. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05. The firm has a market capitalization of $55.03 million, a P/E ratio of -3.32 and a beta of 1.40.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on XGN. Canaccord Genuity Group boosted their price objective on shares of Exagen from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $8.00 target price on shares of Exagen in a research report on Monday, January 13th. Finally, William Blair reissued an “outperform” rating on shares of Exagen in a research note on Wednesday, November 13th.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).